Bullfrog AI Holdings, Inc.

Bullfrog AI Holdings, Inc. is a US-based company that utilizes artificial intelligence to transform drug discovery and development, focusing on enhancing precision medicine through advanced analytical platforms. Founded in 2017 and headquartered in Gaithersburg, US, Bullfrog AI specializes in artificial intelligence for drug development. The company has executed 2 deals and raised USD 0.

20 mn in a Seed round from TEDCO, contributing to its growth. Bullfrog AI specializes in leveraging artificial intelligence to enhance drug discovery and development through its core offerings, which include the bfLEAP™ explainable AI platform and the Bullfrog Data Networks®. These technologies utilize advanced causal AI and graph-based analytics to model complex biological systems, enabling rapid and cost-effective evaluations of genetic influences on cellular behavior. The platform's primary end use cases focus on identifying new drug targets that drive diseases, facilitating precision medicine by optimizing clinical research and streamlining the drug development process.

Bullfrog AI serves a diverse client base that includes pharmaceutical companies, biotechnology firms, and research institutions, particularly in North America and Europe, where it aims to improve the success rates and efficiency of therapeutic development. Bullfrog AI generates revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, primarily by providing access to its proprietary technologies and services. The company engages in B2B transactions, where clients subscribe to its services or enter into contractual agreements for the use of the bfLEAP™ platform and Bullfrog Data Networks®. These partnerships enable clients to harness Bullfrog AI's advanced analytics for drug discovery, which can potentially lead to more effective and safer therapies reaching the market.

Clients typically invest in tailored solutions that enhance their research capabilities and improve their drug development timelines, underscoring the value of Bullfrog AI's offerings in the competitive pharmaceutical landscape. In February 2023, Bullfrog AI Holdings, Inc. raised USD 8. 43 mn in an IPO on the Nasdaq Capital Market, selling 1,297,318 shares at USD 6.

5 per share under the ticker "BFRG". The proceeds from this IPO are intended to support the company’s growth as a public entity. Future strategies include expanding its technological offerings and potentially entering new geographic markets, enhancing its capabilities in drug development.